Benjamin Hohl, CHIEF FINANCIAL OFFICER at Enliven Therapeutics, Inc. (ELVN), sold 6,018 shares at $49.97 ($317K) on 2026-07-17, disclosed to the SEC on 2026-07-21.
Scheduled sale ($317k) by CHIEF FINANCIAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $49.97 | 324 | $16K | 5.1% |
| 2 | $51.48 | 369 | $19K | 6.0% |
| 3 | $52.32 | 2,564 | $134K | 42.3% |
| 4 | $53.38 | 2,638 | $141K | 44.5% |
| 5 | $53.87 | 123 | $7K | 2.1% |
| Total | $52.64 avg | 6,018 |
| $317K |
| 100% |
| Filing → |
| ELVN | SELL | 2026-06-22 | $264K | — | Filing → |
| ELVN | SELL | 2026-03-10 | $296K | — | Filing → |
| ELVN | SELL | 2025-10-01 | $66K | — | Filing → |